09-05-2024 | Sickle Cell Anemia | Original Contribution
Iron absorption in adults with sickle cell anemia: a stable-isotope approach
Authors: Juliana Omena¹, Flávia Fioruci Bezerra¹, Vanessa Monteiro Voll¹, Bernardo Ferreira Braz, Ricardo Erthal Santelli, Carmen Marino Donangelo, Gustavo Federico Jauregui, Andrea Soares Ribeiro, Cláudia dos Santos Cople Rodrigues, Marta Citelli
Published in: European Journal of Nutrition | Issue 6/2024
Login to get accessAbstract
Purpose
Iron absorption in sickle cell anemia (SCA) remains unclear and studies in adults with SCA are scarce. The aim of this study was to evaluate the iron absorption SCA adults and its association with iron status and hepcidin concentration.
Methods
SCA patients (n = 13; SCAtotal) and control participants (n = 10) ingested an oral stable iron isotope (57Fe). Iron absorption was measured by inductively coupled plasma mass spectrometry (ICP-MS) 14 days after isotope administration. Patients with ≥ 1000 ng/mL serum ferritin were considered to present iron overload (IO) (SCAio+; n = 3) and others classified without IO (SCAio-; n = 10).
Results
Iron absorption in the control group ranged from 0.3 to 26.5% (median = 0.9%), while it varied from 0.3 to 5.4% in SCAio+ (median = 0.5%) and from 0.3 to 64.2% in the SCAio- (median = 6.9%). Hepcidin median values were 14.1 ng/mL (3.0–31.9 ng/mL) in SCAio-, 6.2 ng/mL (3.3–7.8 ng/mL) in SCAio + and 6.2 ng/mL (0.6–9.3 ng/mL) in control. Iron absorption was associated with ferritin level (r = − 0.641; p = 0.018) and liver iron concentration (LIC; r = − 0.786; p = 0.036) in the SCAtotal group.
Conclusion
Our data suggest that SCAio- individuals may be at risk of developing primary IO. Simultaneously, secondary IO may induce physiological adaptation, resulting in reduced iron absorption. Further studies evaluating intestinal iron absorption using larger sample sizes should be conducted to help establish a safe nutrition approach to be adopted and to ensure the security of food-fortifying public policies for these patients.
Trial registration
This trial was registered at www.ensaiosclinicos.gov.br (Identifier RBR-4b7v8pt).
Advertisement